Far Infrared Radiation for Sickle Cell Pain Management

NCT ID: NCT00599482

Last Updated: 2009-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2009-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most patients with sickle-cell disease have periodic intensely painful episodes. To manage this pain, we are proposing the drinking of at least 500 mL of water followed by far infrared radiation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Painful sickle cell crises are treated with hydration and analgesics. Ischemia is an absolute or relative shortage of the blood supply to an organ. Relative shortage means the mismatch of blood supply (oxygen delivery) and blood request for adequate oxygenation of tissue.

It is hereby postulated that far infrared radiation of the body will promote blood and oxygen supply to the affected tissues. In addition, the analgesic properties of far infrared will alleviate pain due to the crisis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Sickle Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Far Infrared Radiation

Group Type OTHER

Far Infrared Radiation (5μm to 20μm wavelength)

Intervention Type RADIATION

Far infrared radiation for 30 to 40 minutes during each session.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Far Infrared Radiation (5μm to 20μm wavelength)

Far infrared radiation for 30 to 40 minutes during each session.

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People with sickle cell disease

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GAAD Medical Research Institute Inc.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

GAAD Medical Research Institute Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ken Nedd, M.D.

Role: STUDY_CHAIR

GAAD Medical Research Institute Inc.

Kwasi Donyina, Ph.D.

Role: STUDY_DIRECTOR

GAAD Medical Research Institute Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Centre for Incurable Diseases

Mississauga, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GAAD-SCC-CTP1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TRF-1101 Assessment in Sickle Cell Disease
NCT00773890 TERMINATED PHASE1/PHASE2
Sickle Cell Disease (SCD) Bone Pain Study
NCT05283148 ACTIVE_NOT_RECRUITING NA